Faculty of Health Sciences, University of Debrecen, Debrecen, Hungary.
Doctoral School of Health Sciences, University of Debrecen, Debrecen, Hungary.
BMC Public Health. 2023 Aug 31;23(1):1679. doi: 10.1186/s12889-023-16608-5.
In 2020, globally 685,000 people died, and 2.3 million women were diagnosed with breast cancer. The main cause of cancer deaths among women is breast cancer, which account for 15.5% of all cancer deaths. Most of these could have been avoided with timely diagnosis. The aim of our study was to determine the proportion of breast screening participation in Hungary, and to identify possible factors that may influence breast screening attendance.
Our data were gathered from the cross-sectional European Health Interview Surveys conducted in Hungary in 2009, 2014, and 2019. In terms of categorical characteristics, Pearson's chi-square test was performed to evaluate the differences between people who have attended breast screening within two years and who have only attended more than two years ago. To determine the factors that may have an impact on the uptake of screening, generalized linear model with logit link function regarding binomial probability distribution was executed.
The responses of 2626 women between the age 45-65 were included in our study. In 2009 85% (n=741), in 2014 90% (n=851) and in 2019 87% (n=699) of the respondents claimed to have ever attended a breast screening in their life. In 2009 68% (n=594), in 2014 66% (n=630) and in 2019 64% (n=515) said that they have taken part in breast screening within two years (p=0.331). From 2014 to 2019 (AOR=0.72 [0.57-0.89]) the chance of attending breast screening was decreasing. We observed that both secondary (AOR=1.97 [1.60-2.44]) and tertiary educational level (AOR=2.23 [1.67-3.00]), higher perceived income (AOR=1.54 [1.25-1.90]), and more frequent meeting with the doctor (AOR=1.77 [1.39-2.27]) and with the specialist (AOR=1.88 [1.54-2.28]) appeared as protective factors of breast screening attendance.
Our results show that the lifetime prevalence of breast screening participation is high, however the recommended biennial rate is relatively low. To increase the participation rate, various initiatives would be needed, especially for women in identified risk groups, which are lower educational level, lower perceived income, and less frequent meeting with the doctor and with the specialist.
2020 年,全球有 68.5 万人死亡,230 万女性被诊断患有乳腺癌。女性癌症死亡的主要原因是乳腺癌,占所有癌症死亡人数的 15.5%。如果及时诊断,大多数患者本可以避免死亡。我们的研究目的是确定匈牙利乳腺癌筛查的参与比例,并确定可能影响乳腺癌筛查参与率的因素。
我们的数据来自 2009 年、2014 年和 2019 年在匈牙利进行的欧洲健康访谈调查的横断面研究。对于分类特征,使用 Pearson's chi-square 检验评估了两年内参加过乳腺癌筛查的人与两年前以上参加过乳腺癌筛查的人之间的差异。为了确定可能影响筛查参与率的因素,我们使用了二项概率分布的对数链接函数的广义线性模型。
我们的研究纳入了 2626 名年龄在 45-65 岁之间的女性。2009 年,85%(n=741)的受访者声称一生中曾参加过乳腺癌筛查;2014 年,90%(n=851)的受访者声称一生中曾参加过乳腺癌筛查;2019 年,87%(n=699)的受访者声称一生中曾参加过乳腺癌筛查。2009 年,68%(n=594)的受访者表示他们在两年内参加过乳腺癌筛查;2014 年,66%(n=630)的受访者表示他们在两年内参加过乳腺癌筛查;2019 年,64%(n=515)的受访者表示他们在两年内参加过乳腺癌筛查(p=0.331)。2014 年至 2019 年期间(AOR=0.72 [0.57-0.89]),参加乳腺癌筛查的机会呈下降趋势。我们观察到,中等(AOR=1.97 [1.60-2.44])和高等(AOR=2.23 [1.67-3.00])教育程度、较高的感知收入(AOR=1.54 [1.25-1.90])以及更频繁地与医生(AOR=1.77 [1.39-2.27])和专家(AOR=1.88 [1.54-2.28])会面,这些都被认为是参加乳腺癌筛查的保护因素。
我们的研究结果表明,乳腺癌筛查的终生参与率很高,但推荐的两年一次的筛查率相对较低。为了提高参与率,需要采取各种措施,特别是针对处于特定风险组的女性,如教育程度较低、收入较低、较少与医生和专家见面的女性。